New Delhi, May 04: Serum Institute of India is likely to start phase 3 trials of COVID-19 vaccine Covovax, which it is making in partnership with American company Novavax, by mid-may.
The Drugs Controller General of India has provided its approval to go for the next phase trials.
Covovax is the second vaccine candidate after Covishield that SII is manufacturing.
Dr Abhijit Kadam, Scientist C, coordinating principal investigator from ICMR-National AIDS Research Institute of the trial, said that tentatively phase-3 should start by mid-May.
|